Caco-2 cell permeability assays to measure drug absorption

Expert Opinion on Drug Metabolism and Toxicology

Volumn 1, Issue 2, 2005, Pages 175-185

  Van Breemen, Richard B ^a   Li, Yongmei ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Caco 2 cells; drug absorption; intestinal absorption; intestinal metabolism; liquid chromatography mass spectrometry

Indexed keywords

DRUG;

ABSORPTION; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; DRUG DESIGN; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; PHARMACEUTICS; REVIEW;

ABSORPTION; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33748887871     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.1.2.175     Document Type: Review

References (68)

1. BHATTACHARYYA S: Combinatorial approaches in anticancer drug discovery: recent advances in design and synthesis. Curr. Med. Chem. (2001) 8:1383-1404. (Pubitemid 32894006)
2. CALDWELL GW, RICHIE DM, MASUCCI JA: The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr. Top. Med. Chem. (2001) 1:353-366.
3. HIDALGO IJ, RAUB TJ, BORCHARDT RT: Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology (1989) 96:736-749. (Pubitemid 19057595)
4. ARTURSSON P, PALM K, LUTHMAN K: Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. (2001) 46:27-43.
5. PIDGEON C: Solid phase membrane mimetics: immobilized artificial membranes. Enzyme Microb. Technol. (1990) 12:149-150. (Pubitemid 20081124)
6. LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. (2001) 46:3-26. (Pubitemid 33653411)
7. BALIMANE PV, CHONG S, MORRISON RA: Current methodologies used for evaluation of intestinal permeability and absorption. J. Pharmacol. Toxicol. Methods (2000) 44:301-312. (Pubitemid 32239482)
8. LENNERNAS H: Human intestinal permeability. J. Pharm. Sci. (1998) 87:403-410. (Pubitemid 28175799)
9. USSING HH, ZERAHN K: Active transport of sodium as the source of electric current in the short-circuited isolated frog skin. Reprinted from Acta. Physiol. Scand. (1951) 23:110-127. J. Am. Soc. Nephrol. (1999) 10:2056-2065.
10. LI Y, SHIN YG, YU C et al.: Increasing the throughput and productivity of Caco-2 cell permeability assays using liquid chromatography-mass spectrometry: application to resveratrol absorption and metabolism. Comb. Chem. High Throughput Screen. (2003) 6:757-767. (Pubitemid 38017483)
11. FISHER JM, WRIGHTON SA, WATKINS PB, SCHMIEDLIN-REN P et al.: First-pass midazolam metabolism catalyzed by 1α,25-dihydroxy vitamin D3- modified Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. (1999) 289:1134-1142 (Pubitemid 29191276)
12. BOHETS H, ANNAERT P, MANNENS G et al.: Strategies for absorption screening in drug discovery and development. Curr. Top. Med. Chem. (2001) 1:367-383.
13. HIDALGO IJ: Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. (2001) 1:385-401.
14. MADARA JL, PAPPENHEIMER JR: Structural basis for physiological regulation of paracellular pathways in intestinal epithelia. J. Membr. Biol. (1987)100:149-164. (Pubitemid 18004072)
15. CLARK SL Jr: The ingestion of proteins and colloidal materials by columnar absorptive cells of the small intestine in suckling rats and mice. J. Biophys. Biochem. Cytol. (1959) 5:41-50.
16. HUMPHREY MJ, RINGROSE PS: Peptides and related drugs: a review of their absorption, metabolism, and excretion. Drug Metab. Rev. (1986) 17:283-310. (Pubitemid 17044695)
17. TSUJI A, TAMAI I: Carrier-mediated intestinal transport of drugs. Pharm. Res. (1996) 13:963-977. (Pubitemid 26258994)
18. LEE VH: Membrane transporters. Eur. J. Pharm. Sci. (2000) 11(Suppl. 2):S41-S50.
19. YAMASHITA S, YAMAZAKI Y, MASADA M, NADAI T, KIMURA T, SEZAKI H: Investigations of influx and accumulation processes of beta-lactam antibiotics and their role in the transmural transfer across rat jejunum. J. Pharmacobiodyn. (1986) 9:368-374. (Pubitemid 16087499)
20. KRAMER W, GIRBIG F, GUTJAHR U et al.: Interaction of renin inhibitors with the intestinal uptake system for oligopeptides and beta-lactam antibiotics. Biochim. Biophys. Acta. (1990) 1027:25-30. (Pubitemid 20246541)
21. BAI JP, HU M, SUBRAMANIAN P, MOSBERG HI, AMIDON GL: Utilization of peptide carrier system to improve intestinal absorption: targeting prolidase as a prodrug-converting enzyme. J. Pharm. Sci. (1992) 81:113-116.
22. GOTTESMAN MM, PASTAN I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. (1993) 62:385-427. (Pubitemid 23237876)
23. STEPHENS RH, ONEILL CA, WARHURST A, CARLSON GL, ROWLAND M, WARHURST G: Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther. (2001) 296:584-591. (Pubitemid 32112489)
24. PETERS WH, KREMERS PG: Cytochromes P450 in the intestinal mucosa of man. Biochem. Pharmacol. (1989) 38:1535-1538. (Pubitemid 19123344)
25. KOLARS JC, LOWN KS, SCHMIEDLIN-REN P et al.: CYP3A gene expression in human gut epithelium. Pharmacogenetics (1994) 4:247-259. (Pubitemid 24337433)
26. MCKINNON RA, BURGESS WM, HALL PM, ROBERTS-THOMSON SJ, GONZALEZ FJ, MCMANUS ME: Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut (1995) 36:259-267.
27. WATKINS PB, WRIGHTON SA, SCHUETZ EG, MOLOWA DT, GUZELIAN PS: Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J. Clin. Invest. (1987) 80:1029-1036. (Pubitemid 18075638)
28. DE WAZIERS I, CUGNENC PH, YANG CS, LEROUX JP, BEAUNE PH : Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. (1990) 253:387-394. (Pubitemid 20141526)
29. HO NFH, PARK JY, MOROZOWICH W, HIGUCHI WI: In:Design of Biopharmaceutical Properties Through Prodrugs and Analogs. EB Roche (Ed.), American Pharmaceutical Association, Academy of Pharmaceutical Sciences. Washington, DC, US (1977).
30. KANSY M, SENNER F, GUBERNATOR K: Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. (1998) 41:1007-1010. (Pubitemid 28207375)
31. AUNGST BJ, NGUYEN NH, BULGARELLI JP, OATES-LENZ K: The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm. Res. (2000) 17:1175-1180.
32. LENNERNAS H, NYLANDER S, UNGELL AL: Jejunal permeability: a comparison between the Ussing chamber technique and the single-pass perfusion in humans. Pharm. Res. (1997) 14:667-671. (Pubitemid 27220288)
33. ARTURSSON P: Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. (1990) 79:476-482. (Pubitemid 20221389)
34. HILGERS AR, CONRADI RA, BURTON PS: Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm. Res. (1990) 7:902-910. (Pubitemid 20349761)
35. AUDUS KL, BARTEL RL, HIDALGO IJ, BORCHARDT RT: The use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharm. Res. (1990) 7:435-451. (Pubitemid 20322193)
36. HUNTER J, JEPSON MA, TSURUO T, SIMMONS NL, HIRST BH: Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. (1993) 268:14991-14997. (Pubitemid 23206648)
37. WALLE UK, GALIJATOVIC A, WALLE T: Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem. Pharmacol. (1999) 58:431-438. (Pubitemid 29281542)
38. ARTURSSON P, KARLSSON J: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. (1991) 175:880-885.
39. GRES MC, JULIAN B, BOURRIE M et al.: Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm. Res. (1998) 15:726-733. (Pubitemid 28275649)
40. YEE S: In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm. Res. (1997) 14:763-766. (Pubitemid 27281671)
41. WU SJ, ROBINSON JR: Transport of human growth hormone across Caco-2 cells with novel delivery agents: evidence for P-glycoprotein involvement. J. Control. Release. (1999) 62:171-177. (Pubitemid 29486495)
42. YU DK: The contribution of Pglycoprotein to pharmacokinetic drug-drug interactions. J. Clin. Pharmacol. (1999) 39:1203-1211.
43. WILSON G, HASSAN IF, DIX CJ et al.: Transport and permeability properties of human Caco-2 cells: an in vitro model of the intestinal epithelial cell barrier. J. Control. Release (1990) 11:25-40. (Pubitemid 20070083)
44. PAINE MF, KHALIGHI M, FISHER JM et al.: Characterization of interintestinal and intraintestinal variations in human CYP3Adependent metabolism. Pharmacol. Exp. Ther. (1997) 283:1552-1562. (Pubitemid 28016533)
45. GAN LS, MOSELEY MA, KHOSLA B et al.: CYP3A-like cytochrome P450- mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab. Dispos. (1996) 24:344-349.
46. PRUEKSARITANONT T, GORHAM LM, HOCHMAN JH, TRAN LO, VYAS KP: Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab. Dispos. (1996) 24:634-642. (Pubitemid 26170714)
47. SCHMIEDLIN-REN P, THUMMEL KE, FISHER JM, PAINE MF, LOWN KS, WATKINS PB: Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α,25- dihydroxyvitamin D3. Mol. Pharmacol. (1997) 51:741-754. (Pubitemid 27224679)
48. MEUNIER V, BOURRIE M, BERGER Y, FABRE G: The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol. Toxicol. (1995) 11:187-194.
49. CARRIERE V, CHAMBAZ J, ROUSSET M: Intestinal responses to xenobiotics. Toxicol. In Vitro (2001) 15:373-378.
50. BARANCZYK-KUZMA A, GARREN JA, HIDALGO IJ, BORCHARDT RT: Substrate specificity and some properties of phenol sulfotransferase from human intestinal Caco-2 cells. Life Sci. (1991) 49:1197-1206.
51. MANNA C, GALLETTI P, MAISTO G, CUCCIOLLA V, DANGELO S, ZAPPIAV: Transport mechanism and metabolism of olive oil hydroxytyrosol in Caco-2 cells. FEBS Lett. (2000) 470:341-344. (Pubitemid 30169289)
52. YU C, SHIN YG, CHOW A et al.: Human, rat, and mouse metabolism of resveratrol. Pharm. Res. (2002) 19:1907-1914. (Pubitemid 36016041)
53. VAIDYANATHAN JB, WALLE T: Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm. Res. (2001) 18:1420-1425. (Pubitemid 32977247)
54. HU M, CHEN J, LIN H: Metabolism of flavonoids via enteric recycling: mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J. Pharmacol. Exp. Ther. (2003) 307:314-321. (Pubitemid 37151923)
55. CHONG S, DANDO SA, MORRISON RA: Evaluation of Biocoat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity. Pharm. Res. (1997) 14:1835-1837.
56. LIANG E, CHESSIC K, YAZDANIAN M: Evaluation of an accelerated Caco-2 cell permeability model. J. Pharm. Sci. (2000) 89:336-345. (Pubitemid 30152434)
57. CHIKHALE PJ, BORCHARDT RT: Metabolism of L-alpha-methyldopa in cultured human intestinal epithelial (Caco-2) cell monolayers. Comparison with metabolism in vivo. Drug Metab. Dispos. (1994) 22:592-600. (Pubitemid 24244870)
58. UCPINAR SD, STAVCHANSKY S: Quantitative determination of saquinavir from Caco-2 cell monolayers by HPLC-UV. High performance liquid chromatography. Biomed. Chromatogr. (2003) 17:21-25. (Pubitemid 36240664)
59. CALDWELL GW, EASLICK SM, GUNNET J, MASUCCI JA, DEMAREST K: In vitro permeability of eight beta-blockers through Caco-2 monolayers utilizing liquid chromatography/electrospray ionization mass spectrometry. J. Mass Spectrom. (1998) 33:607-614. (Pubitemid 28343376)
60. STEVENSON CL, AUGUSTIJNS PF, HENDREN RW: Use of Caco-2 cells and LC/MS/MS to screen a peptide combinatorial library for permeable structures. Int. J. Pharm. (1999)177:103-115. (Pubitemid 29067431)
61. WANG Z, HOP CE, LEUNG KH, PANG J: Determination of in vitro permeability of drug candidates through a caco-2 cell monolayer by liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. (2000) 35:71-76. (Pubitemid 30060154)
62. ROMANYSHYN L, TILLER PR, HOP CE: Bioanalytical applications of fast chromatography to high-throughput liquid chromatography/tandem mass spectrometric quantitation. Rapid Commun. Mass Spectrom. (2000) 14:1662-1668.
63. FUNG EN, CHU I, LI C et al.: Higherthroughput screening for Caco-2 permeability utilizing a multiple sprayer liquid chromatography/tandem mass spectrometry system. Rapid Commun. Mass Spectrom. (2003) 17:2147-2152. (Pubitemid 37093091)
64. BU HZ, POGLOD M, MICETICH RG, KHAN JK: High-throughput caco-2 cell permeability screening by cassette dosing and sample pooling approaches using direct injection/on-line guard cartridge extraction/ tandem mass spectrometry. Rapid Commun. Mass Spectrom. (2000) 14:523-528. (Pubitemid 30153005)
65. LAITINEN L, KANGAS H, KAUKONEN AM et al.: N-in-one permeability studies of heterogeneous sets of compounds across Caco-2 cell monolayers. Pharm. Res. (2003) 20:187-197. (Pubitemid 36269725)
66. TANNERGREN C, LANGGUTH P, HOFFMANN KJ: Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity. Pharmazie (2001) 56:337-342. (Pubitemid 32323128)
67. POON GK, KWEI G, WANG R et al.: Integrating qualitative and quantitative liquid chromatography/tandem mass spectrometric analysis to support drug discovery. Rapid Commun. Mass Spectrom. (1999) 13:1943-1950. (Pubitemid 29456352)
68. NIESSEN WM: Progress in liquid chromatography-mass spectrometry instrumentation and its impact on highthroughput screening. J. Chromatogr. A. (2003) 1000:413-436. (Pubitemid 36638468)